Gå direkt till huvudinnehållet

Rosacea

Senast reviderad:
Sakkunnig:
Definition:
Kronisk inflammatorisk hudsjukdom i ansiktet med kvarvarande eller recidiverande episoder med symmetrisk rodnad, ödem, telangiektasier, papler, pustler, rinofyma och ögonsymtom.
Förekomst:
Debuterar vanligen mellan 20 och 50 års ålder, prevalens 5 %.
Symtom:
Erytem och eventuell papler och pustler som är symmetriskt utbredda i ansiktet. Kan också leda till förjockning av huden med knölar.
Kliniska fynd:
Erytem och eventuellt papler, pustler och telangiektasier på pannan, kinder och näsa. Eventuellt ögonsymtom eller rinofyma.
Diagnostik:
Typisk klinisk bild.
Behandling:
Undvika utlösande faktorer. Lokalbehandling, eventuellt peroral antibiotika eller isotretinoin vid uttalade besvär. Kirurgisk behandling kan vara aktuellt vid rinofyma.
  1. van Zuuren EJ. Rosacea. N Engl J Med 2017; 377: 1754-64. pmid:29091565 PubMed  
  2. Oge' LK, Muncie HL, Phillips-Savoy AR. Rosacea: Diagnosis and Treatment. Am Fam Physician. 2015 Aug 1;92(3):187-96. PMID: 26280139 PubMed  
  3. Barakji YA, Rønnstad ATM, Christensen MO et al. Assessment of Frequency of Rosacea Subtypes in Patients With Rosacea: A Systematic Review and Meta-analysis. JAMA Dermatol. 2022 Apr 6. Epub ahead of print. PMID: 35385049. PubMed  
  4. Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018 Aug;179(2):282-289. doi: 10.1111/bjd.16481. Epub 2018 May 31. PMID: 29478264 PubMed  
  5. Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res. 2018 Dec 3;7:F1000 Faculty Rev-1885. doi: 10.12688/f1000research.16537.1. PMID: 30631431 PubMed  
  6. Mobacken H, Berg M, Angesjö E, Dunér K, Svensson M, Synnerstad I. Dags att minska användningen av antibiotika vid rosacea - Isotretinoin bör övervägas vid frekventa recidiv – lokalbehandling fortfarande förstahandsterapi Time to limit the use of antibiotics in rosacea!. Lakartidningen. 2018 Apr 24;115:EY3H. Swedish. PMID: 29714807 PubMed  
  7. Aldrich N, Gerstenblith M, Fu P, Tuttle MS, Varma P, Gotow E, Cooper KD, Mann M, Popkin DL. Genetic vs Environmental Factors That Correlate With Rosacea: A Cohort-Based Survey of Twins. JAMA Dermatol. 2015 Nov;151(11):1213-9. doi: 10.1001/jamadermatol.2015.2230. PMID: 26307938 PubMed  
  8. Aroni K, Tsagroni E, Kavantzas N, et al. Study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res 2008; 300: 125-31. pmid:18071725 PubMed  
  9. Gravina AG, Federico A, Ruocco E, et al. Helicobacter pylori infection but not small intestinal overgrowth may play a pathogenetic role in rosacea. United European Gastroenterology Journal 2015; 3: 17-24. PMID: 25653855 PubMed  
  10. Yang X. Relationship between Helicobacter pylori and Rosacea: review and discussion. BMC Infect Dis. 2018 Jul 11;18(1):318. PMID: 29996790 PubMed  
  11. Whitfeld M, Gunasingam N, Leow JL, et al. Staphylococcus epidermidis: A possible role in the pustules of rosacea. J Am Acad Dermatol 2011; 64(1): 49-52. PMID: 20943287 PubMed  
  12. Ahn, C. S., & Huang, W. W. (2018). Rosacea Pathogenesis. Dermatologic Clinics, 36(2), 81–86. PMID: 29499802 PubMed  
  13. Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J, Thiboutot D. Rosacea comorbidities and future research: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018 Jan;78(1):167-170. doi: 10.1016/j.jaad.2017.06.150. PMID: 29102687 PubMed  
  14. Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013;69(6 suppl 1):S15–S26. PMID: 24229632 PubMed  
  15. Zierl S, Hildebrand JA, Guertler A et al. Clinical clues to identify patients with ocular rosacea - a Germany-wide epidemiologic analysis. Int J Dermatol. 2022 Jul;61(7):880-885.Epub 2022 May 17. PMID: 35579395 PubMed  
  16. van Zuuren EJ, Fedorowicz Z, Carter B et al. Interventions for rosacea: abridged updated Cochrane systematic review including GRADE assessments. Br J D 2015; 173 (3): 651-62. pmid:26099423 PubMed  
  17. Läkemedelsverket (2016). Uppdaterade rekommendationer för användning av Mirvaso gel. (Hämtad 2016-11-03) lakemedelsverket.se  
  18. Taieb A, Khemis A, Ruzicka T, et al. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol. 2016 May;30(5):829-36. PMID: 26691278 PubMed  
  19. Taieb A, Ortonne JP, Ruzicka T, et al; Ivermectin Phase III study group. Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172(4):1103-10. PubMed  
  20. Taieb A, Khemis A, Ruzicka T, et al; Ivermectin Phase III Study Group. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol. 2016;30(5):829-36 PubMed  
  21. Krausz AE, Goldberg DJ, Ciocon DH, Tinklepaugh AJ. Procedural management of rhinophyma: A comprehensive review. J Cosmet Dermatol 2018; 17: 960-7. pmid:30225926 PubMed  
  22. Huldt-Nystrøm T, Danielsen K, Li X, Stangeland KZ. Rosacea Rosacea. Tidsskr Nor Laegeforen. 2017 Oct 2;137(18). Norwegian. doi: 10.4045/tidsskr.16.0657. PMID: 28972327 PubMed  
  23. Hua TC, Chung PI, Chen YJ, et al. Cardiovascular comorbidities in patients with rosacea: A nationwide case-control study from Taiwan. J Am Acad Dermatol 2015; 73: 249-54. PMID: 26004520 PubMed  
  • Anna Nager, docent och specialist i allmänmedicin, Karolinska institutet